licensing

News

Amgen pays Kyowa $400m upfront for OX40 eczema drug

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi

News

Social psychology concept as a group of connected network of people icons with one individual brain illuminated as a symbol for sociology and group interaction.

Biogen bolsters ischaemic stroke pipeline with thrombolytic ...

Biogen has licensed a new drug from Japanese biotech TMS that it hopes could provide a big advance on an old treatment approach – using clot-busting thrombolytic drugs to treat ischaemic st

News

Merck KGaA offloads failed MEK programme to startup Day One

US biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s pipeline for years, in the hope of giving it a new lease of life.

News

Lilly adds to pain pipeline with Asahi Kasei licensing deal

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t

News

Bayer joins the COVID-19 vaccine push, backing CureVac shot

Shortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to roll the shot out at scale if it works as hoped.

News